Novartis’ recently launched FocalView app will be used in a new study to remotely collect electronic device reported outcome measurements (eDROs) from 150,000 users.
More efficient clinical trials may reduce global CRO revenue, potentially slowing adoption of new technology, says Otsuka director – noting that the industry doesn’t often take operational risks, but it must.
Keine Kommentare:
Kommentar veröffentlichen